Delivery : 24-72 Working Hours
Report Code: LS10148
Category : Pharmaceuticals
Restless legs syndrome or RLS is a neurological disease. RLS is also called as Willis-Ekbom disease. Patients suffering from RLS disease have an irresistible desire to move their feet. The continual movement of the legs leads to pain in the limbs, which leads to the unusual sleep pattern of patients.
Restless legs syndrome increases at night when the patient is at rest. RLS are common in both, male and female; however the disease has its highest impact on woman who are elderly or in some cases woman with the age 35 to 50 years. Some of the most common symptoms of the restless legs syndrome are continue itching and pain in the legs, and unusual sleep pattern. The restless legs syndrome affects the quality of life of the person suffering from the disease.
The exact reason behind the restless legs syndrome is not known precisely, however, it is believed the disease is caused due to genetic factors or due to iron deficiency in the brain or due to the disorders in dopaminergic balance.
The exact treatment of this disease is not present till now. However the available drug in the market helps in the indicative treatment of the disease. Some of the drug in the restless legs syndrome market such as sulfonamide by safinamide by Newron Pharmaceuticals reduces the symptoms by novel action such as potent, reversible and selective inhibition of MAO-B, without disturbing the MAO-A and dopamine uptake. This enhances the glutamate release and dopaminergic function of the patients; it also reduces the dopamine degradation. One other drug: SER-214 manufacture by Serina is used widely in the restless legs syndrome treatment; it uses a water-soluble polymer poly (2-alkyloxazoline)-based drug delivery technology this drug can be combined with the polymer and transported to the patients.
The currently available drugs in restless legs syndrome can only delivered to target specific patients for symptomatic relief only. Moreover, some of the adverse effects such as nervous system disorders that include headache, dizziness, sedation, nausea, flatulence and dry mouth. Psychiatric disorders, including decreased libido and depression. Metabolism and nutritional disorders, including increased appetite and weight gain; ear disorder, labyrinth disorders and other common disorders such as irritability, fatigue, and peripheral edema are related with the use of these drugs. Thus the treatment procedure for the restless legs syndrome is still not very popular and not adopted by the healthcare service provider on a larger part. The development of new drugs that have higher efficiency and minimal side effect would be highly appreciated in the restless legs syndrome treatment market.
Based on the different product type the global restless legs syndrome market can be broadly classified as Mirapex/Sifrol/Mirapexin, Neupro/Leganto, Requip, and HORIZANT/Regnite. On the basis various disease type the global restless legs syndrome market can be broadly bifurcated as etiology and pathogenesis, iron deficiency, genetic factors, neurological disturbances and others. Based on the mode of the therapy the global restless legs syndrome market can be broadly segmented into two broad categories: pharmacological therapy and non-pharmacological therapy.
Some of the major players operating in the global restless legs syndrome market include, GlaxoSmithKline plc., Ligand Pharmaceuticals Incorporated, axxonis Pharma AG, Kyowa Hakko Kirin Co., Jazz Pharmaceuticals, Inc., Omeros Corporation, Manhattan Pharmaceuticals, Boehringer Ingelheim GmbH, UCB SA